Thu Feb 20 05:21:33 UTC 2025: ## Aurobindo Pharma Warehouse Receives US FDA Warning
**Hyderabad, February 20, 2025** – Aurobindo Pharma has announced that a US Food and Drug Administration (FDA) inspection of its subsidiary’s New Jersey warehouse resulted in an “Official Action Indicated” (OAI) classification. The inspection, conducted from May 13-15, 2024, focused on compliance with the Drug Supply Chain Security Act (DSCSA) and yielded five observations.
While the company stated it does not anticipate any immediate impact on its business, the OAI classification suggests the FDA recommends regulatory or administrative action. The FDA classifies post-inspection findings as either No Action Indicated, Voluntary Action Indicated, or OAI. Aurobindo Pharma shares fell 1.17% following the announcement. The company maintains its commitment to working with the FDA to improve compliance.
First Piper 